CPG
VRTX icon

Cornerstone Planning Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Cornerstone Planning Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$49.2K Sell
116
-8
-6% -$3.73K 0.01% 408
2025
Q4 		$59.3K Buy
124
+7
+6% +$3.02K 0.01% 308
2025
Q3 		$599 Buy
117
+2
+2% +$836 ﹤0.01% 1436
2025
Q2 		$43.1K Sell
115
-10
-8% -$4.61K 0.01% 266
2025
Q1 		$61.6K Buy
125
+66
+112% +$30.8K 0.01% 201
2024
Q4 		$26.2K Buy
59
+1
+2% +$464 0.01% 271
2024
Q3 		$27.3K Sell
58
-21
-27% -$10.1K 0.01% 259
2024
Q2 		$37.7K Sell
79
-12
-13% -$5.21K 0.01% 232
2024
Q1 		$36.5K Sell
91
-47
-34% -$19.9K 0.01% 210
2023
Q4 		$56.2K Buy
138
+42
+44% +$15.5K 0.02% 170
2023
Q3 		$33.4K Buy
96
+1
+1% +$350 0.01% 236
2023
Q2 		$33.4K Buy
+95
New +$32K 0.01% 321
2022
Q4 		$13.2K Buy
+43
New +$13.1K 0.01% 556

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cornerstone Planning Group's VRTX Position: Q1 2026 in Review

Cornerstone Planning Group reduced its Vertex Pharmaceuticals (VRTX) stake by 6.5% in Q1 2026, selling an estimated $3.73K and leaving 116 shares worth $49.2K. The position accounts for 0.01% of the portfolio, ranked #408.

Cornerstone Planning Group first reported a position in VRTX in Q4 2022 and has held it in 13 quarters since. The position peaked at $61.6K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Cornerstone Planning Group held 116 shares of Vertex Pharmaceuticals worth $49.2K as of Q1 2026.
  • Cornerstone Planning Group sold 8 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.73K.
  • Vertex Pharmaceuticals made up 0.01% of Cornerstone Planning Group's portfolio in Q1 2026, its #408 holding.
  • Cornerstone Planning Group first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
  • Cornerstone Planning Group's Vertex Pharmaceuticals position peaked at $61.6K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Cornerstone Planning Group's 13F filing for Q1 2026, filed 6 May 2026.